Wells Fargo & Company My Md Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.22 - $0.58 $7 - $20	36 Added 0.69%	5,259 $1,000
Q3 2023 Nov 13, 2023	SELL	$0.47 - $1.87 $74,269 - $295,499	-158,021 Reduced 96.8%	5,223 $3,000
Q2 2023 Aug 15, 2023	BUY	$1.44 - $2.26 $126,760 - $198,943	88,028 Added 117.03%	163,244 $244,000
Q1 2023 May 12, 2023	BUY	$1.1 - $2.86 $82,504 - $214,511	75,004 Added 35379.25%	75,216 $129,000
Q4 2022 Feb 13, 2023	SELL	$0.92 - $96.0 $908 - $94,848	-988 Reduced 82.33%	212 $0
Q3 2022 Nov 14, 2022	BUY	$2.22 - $82.2 $2 - $82	1 Added 0.08%	1,200 $4,000
Q2 2022 Aug 12, 2022	SELL	$2.0 - $4.78 $774 - $1,849	-387 Reduced 24.4%	1,199 $2,000
Q1 2022 May 16, 2022	BUY	$3.34 - $6.05 $6 - $12	2 Added 0.13%	1,586 $8,000
Q4 2021 Feb 14, 2022	SELL	$5.46 - $9.69 $7,491 - $13,294	-1,372 Reduced 46.41%	1,584 $10,000
Q3 2021 Nov 15, 2021	SELL	$4.64 - $7.94 $14,435 - $24,701	-3,111 Reduced 51.28%	2,956 $21,000
Q2 2021 Aug 16, 2021	BUY	$3.39 - $6.98 $20,567 - $42,347	6,067 New	6,067 $38,000

30.2K

Ticker MYMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,470,000
Market Cap $67.5M
Description
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and o...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.